Results 11 to 20 of about 809,825 (355)

Targeting the EGFR in ovarian cancer with the tyrosine kinase inhibitor ZD1839 (“Iressa”). [PDF]

, 2002
The modulating effects of the orally active epidermal growth factor receptor-specific tyrosine kinase inhibitor ZD 1839 (‘Iressa’) on cell growth and signalling were evaluated in four ovarian cancer cell lines (PE01, PE04, SKOV-3, OVCAR-5) that express ...
A Berchuck, A Levitzki, A Ritchie, AE Wakeling, AJ Crew, BJB Simpson, BJB Simpson, BS Verbeek, D Ferry, DW Fry, F Ciardiello, FM Sirotnak, G Carpenter, J Baselga, J F Smyth, J M Sewell, J Mendelsohn, JMS Bartlett, JR Woodburn, K G Macleod, K Morishige, K Stromberg, MA Olayioye, MP Ezekial, MW Kunkel, P Chen, S P Langdon, SE Egan, SP Langdon, WS Chen   +29 more
core   +2 more sources

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Cancers, 2017
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast ...
Ping Wee, Zhixiang Wang
semanticscholar   +1 more source

Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor [PDF]

, 2016
To compare estrogen (ER), progesterone (PR), and human epidermal growth factor-2 (HER2) receptor expression in the primary tumor of patients affected by choroidal metastases from breast carcinoma (BC) versus those with extraocular ...
Frizziero, Luisa, Midena, Edoardo, Miglionico, Giacomo, Parrozzani, Raffaele, Perrini, Pierdavide, Pilotto, Elisabetta, Pulze, Serena, Testi, Ilaria   +7 more
core   +1 more source

Inhibiting epidermal growth factor receptor at a distance. [PDF]

, 2014
The epidermal growth factor receptor (EGFR) tyrosine kinase is implicated in a large number of human cancers. Most EGFR inhibitors target the extracellular, growth factor-binding domain or the intracellular, ATP-binding domain. Here we describe molecules
Denton, Elizabeth, Schepartz, Alanna, Sinclair, Julie   +2 more
core   +2 more sources

Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)

Tumor Biology, 2017
The use of trastuzumab in patients with breast cancer that overexpresses human epidermal growth factor receptor 2 has significantly improved treatment outcomes.
Marianne Nordlund Broughton, Arne Westgaard, Elisabeth Paus, Miriam Øijordsbakken, Karoline J Henanger, Bjørn Naume, Trine Bjøro   +6 more
doaj   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report [PDF]

, 2013
BACKGROUND: Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear.
Akio Saiura, Eiji Shinozaki, Hiroki Osumi, Masashi Ueno, Mitsukuni Suenaga, Mun Mingyon, Nobuyuki Mizunuma, Satoshi Matsusaka, Toshiharu Yamaguchi   +8 more
core   +1 more source

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

Genome Medicine, 2017
Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to ...
Leanne G. Ahronian, Ryan B. Corcoran
doaj   +1 more source

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium [PDF]

, 2014
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized
Ali, H Raza, Benitez, Javier, Blomqvist, Carl, Blows, Fiona M, Bolla, Manjeet K, Brinton, Louise, Brock, Ian W, Broeks, Annegien, Brook, Mark N, Caldas, Carlos, Couch, Fergus J, Coulson, Penny, Cox, Angela, Cross, Simon S, Daley, Frances, Dawson, Sarah-Jane, Devillee, Peter, Easton, Douglas F, Fagerholm, Rainer, Figueroa, Jonine, García-Closas, Montserrat, Gazinska, Patrycja, Heikkilä, Päivi, Hollestelle, Antoinette, Howat, William J, Johnson, Nicola, Jones, Louise, Kataja, Vesa, Kosma, Veli-Matti, Lissowska, Jolanta, Mannermaa, Arto, McDuffus, Leigh-Anne, Menéndez, Primitiva, Mesker, Wilma E, Miller, Jodi, Morris, Lorna, Nevanlinna, Heli, Olson, Janet E, Perez, Jose Ignacio Arias, Pharoah, Paul D, Pinder, Sarah, Provenzano, Elena, Reed, Malcolm W, Sanders, Joyce, Sawyer, Elinor J, Schmidt, Marjanka K, Seyaneve, Caroline M, Sherman, Mark E, Sironen, Reijo, van Deurzen, Carolien H M, Visscher, Daniel, Wesseling, Jelle   +51 more
core   +6 more sources